Apollo Health Ventures is a transatlantic early-stage venture capital firm that co-founds and invests in transformative healthcare and biotechnology companies targeting age-related diseases and aging. The firm operates from offices in Berlin, Luxembourg, and Boston.
58% of their portfolio is in Biotech & Life Sciences. Their most common stage is seed (58% of deals). Average disclosed round size is $50.4M (across 16 rounds with reported amounts).
Portfolio
15
Fund Size
$180M
Top Stage
Seed
Last 12 Mo
3
Team
NR
Nils Regge
Co-Founder & General Partner
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
19 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Cognito | Series C | $105M | Mar 2026 |
 Scripta Therapeutics | Seed | $12M | Nov 2025 |
 Scripta | Seed | $12M | Nov 2025 |
 Therini Bio | Series A | $39M | May 2025 |
 Haya Therapeutics | Series A | $65M | May 2025 |
| Scripta | Seed | — | Jan 2025 |
| RRefoxy Pharmaceuticals | Seed | $10M | Dec 2024 |
 Booster Therapeutics | Seed | $15M | Oct 2024 |
 Aeovian Pharmaceuticals | Unknown | $50M | Mar 2024 |
 Refoxy Pharma | Seed | — | Jan 2024 |
| CCleara Biotech | Seed | $2.5M | Sep 2022 |
 Auron Therapeutics | Series A | $48M | Jul 2022 |
| Haya Therapeutics | Seed | $5M | Feb 2022 |
| Haya Therapeutics | Seed | $5M | Jan 2021 |
| BBionyra | Series A | $165M | — |
| Refoxy Pharma | Seed | — | — |
 Bionyra Pharma | Series A | $165M | — |
 Cleara | Seed | $2.5M | — |
 Cognito Therapeutics | Series C | $105M | — |
Top Co-Investors
Sofinnova Partners6 shared
Arkin Bio Ventures3 shared
Eli Lilly and Company3 shared
Oxford Science Enterprises3 shared
Sanofi Ventures3 shared
High-Tech Gründerfonds3 shared
YZR Capital2 shared
Parkwalk Advisors2 shared
AlbionVC2 shared
Oxford University Innovation2 shared
VIVES Partners2 shared
Jeito Capital2 shared
Sixty Degree Capital2 shared
The Longevity Fund2 shared
ROM Utrecht Region2 shared
IAG Capital Partners2 shared
Morningside2 shared
Starbloom Capital2 shared
Humboldt Fund2 shared
Last updated: 20 October 2026